Literature DB >> 25077930

Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients.

I L Han Choo1, Stephen F Carter, Michael L Schöll, Agneta Nordberg.   

Abstract

PURPOSE: The Alzheimer's disease (AD) pathology is characterized by fibrillar amyloid deposits and neurofibrillary tangles, as well as the activation of astrocytosis, microglia activation, atrophy, dysfunctional synapse, and cognitive impairments. The aim of this study was to test the hypothesis that astrocytosis is correlated with reduced gray matter density in prodromal AD.
METHODS: Twenty patients with AD or mild cognitive impairment (MCI) underwent multi-tracer positron emission tomography (PET) studies with (11)C-Pittsburgh compound B ((11)C-PIB), (18) F-Fluorodeoxyglucose ((18) F-FDG), and (11)C-deuterium-L-deprenyl ((11)C-DED) PET imaging, as well as magnetic resonance imaging (MRI) scanning, cerebrospinal fluid (CSF) biomarker analysis, and neuropsychological assessments. The parahippocampus was selected as a region of interest, and each value was calculated for four different imaging modalities. Correlation analysis was applied between DED slope values and gray matter (GM) densities by MRI. To further explore possible relationships, correlation analyses were performed between the different variables, including the CSF biomarker.
RESULTS: A significant negative correlation was obtained between DED slope values and GM density in the parahippocampus in PIB-positive (PIB + ve) MCI patients (p = 0.025) (prodromal AD). Furthermore, in exploratory analyses, a positive correlation was observed between PIB-PET retention and DED binding in AD patients (p = 0.014), and a negative correlation was observed between PIB retention and CSF Aβ42 levels in MCI patients (p = 0.021), while the GM density and CSF total tau levels were negatively correlated in both PIB + ve MCI (p = 0.002) and MCI patients (p = 0.001). No significant correlation was observed with FDG-PET and with any of the other PET, MRI, or CSF biomarkers.
CONCLUSIONS: High astrocytosis levels in the parahippocampus of PIB + ve MCI (prodromal AD) patients suggest an early preclinical influence on cellular tissue loss. The lack of correlation between astrocytosis and CSF tau levels, and a positive correlation between astrocytosis and fibrillar amyloid deposition in clinical demented AD together indicate that parahippocampal astrocytosis might have some causality within the amyloid pathology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25077930     DOI: 10.1007/s00259-014-2859-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  41 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

Review 2.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

3.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.

Authors:  J S Fowler; R R MacGregor; A P Wolf; C D Arnett; S L Dewey; D Schlyer; D Christman; J Logan; M Smith; H Sachs
Journal:  Science       Date:  1987-01-23       Impact factor: 47.728

4.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

5.  High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Authors:  A Forsberg; O Almkvist; H Engler; A Wall; B Långström; A Nordberg
Journal:  Curr Alzheimer Res       Date:  2010-02       Impact factor: 3.498

Review 6.  Astrocytes in Alzheimer's disease.

Authors:  Alexei Verkhratsky; Markel Olabarria; Harun N Noristani; Chia-Yu Yeh; Jose Julio Rodriguez
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

7.  The importance of impaired physical health and age in normal cognitive aging.

Authors:  Ingvar Bergman; Mari Blomberg; Ove Almkvist
Journal:  Scand J Psychol       Date:  2007-04

8.  Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

Authors:  Renaud La Joie; Audrey Perrotin; Louisa Barré; Caroline Hommet; Florence Mézenge; Méziane Ibazizene; Vincent Camus; Ahmed Abbas; Brigitte Landeau; Denis Guilloteau; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

10.  Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.

Authors:  Wolfgang J Streit; Heiko Braak; Qing-Shan Xue; Ingo Bechmann
Journal:  Acta Neuropathol       Date:  2009-06-10       Impact factor: 17.088

View more
  26 in total

1.  (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Authors:  Eunkyung Park; Jean-Dominique Gallezot; Aracely Delgadillo; Shuang Liu; Beata Planeta; Shu-Fei Lin; Kevin C O'Connor; Keunpoong Lim; Jae-Yun Lee; Anne Chastre; Ming-Kai Chen; Nicholas Seneca; David Leppert; Yiyun Huang; Richard E Carson; Daniel Pelletier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

2.  In Vivo Metabolic Trapping Radiotracers for Imaging Monoamine Oxidase-A and -B Enzymatic Activity.

Authors:  Allen F Brooks; Xia Shao; Carole A Quesada; Phillip Sherman; Peter J H Scott; Michael R Kilbourn
Journal:  ACS Chem Neurosci       Date:  2015-10-01       Impact factor: 4.418

Review 3.  Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia.

Authors:  William C Kreisl; Ioline D Henter; Robert B Innis
Journal:  Adv Pharmacol       Date:  2017-11-10

4.  Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease.

Authors:  Malin Olsen; Ximena Aguilar; Dag Sehlin; Xiaotian T Fang; Gunnar Antoni; Anna Erlandsson; Stina Syvänen
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 5.  Neuroinflammation in Neurodegenerative Disorders-a Review.

Authors:  Martin Schain; William Charles Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

Review 6.  Astrocytes in Neurodegeneration: Inspiration From Genetics.

Authors:  Jingxuan Huang; Chunyu Li; Huifang Shang
Journal:  Front Neurosci       Date:  2022-06-24       Impact factor: 5.152

Review 7.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

Review 8.  Glial biomarkers in human central nervous system disease.

Authors:  Gwenn A Garden; Brian M Campbell
Journal:  Glia       Date:  2016-05-26       Impact factor: 7.452

9.  Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.

Authors:  Elena Rodriguez-Vieitez; Ruiqing Ni; Balázs Gulyás; Miklós Tóth; Jenny Häggkvist; Christer Halldin; Larysa Voytenko; Amelia Marutle; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-17       Impact factor: 9.236

Review 10.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.